Belharra and Sanofi join forces on next-gen drug research

19 June 2024
belharra_large

US chemoproteomics start-up Belharra Therapeutics, has entered into a strategic collaboration with French pharma major Sanofi (Euronext: SAN) to advance the discovery of novel small molecule therapeutics for immunological diseases.

The collaboration will leverage San Diego-based Belharra’s proprietary non-covalent chemoproteomics platform to screen and validate hits against undisclosed Sanofi-designated immunology targets.

Belharra emerged from stealth with a $50 million Series A financing and multi-year collaboration with Roche (ROG: SIX) subsidiary Genentech providing $80 million up front in January this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical